← All trials
NCT03520439
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2018
- Primary completion
- May 1, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Zhejiang UniversitySponsor investigator
- Anhui Province Cancer HospitalCollaborator
- Wenzhou Medical UniversityCollaborator
- Huzhou UniversityCollaborator
- Jiaxing Maternity and Child Health Care HospitalCollaborator
- Jinhua Central HospitalCollaborator
- Ningbo Maternity and Child Care HospitalCollaborator
- Shaoxing People's HospitalCollaborator
- Shaoxing Women and Children's HospitalCollaborator
- Ningbo UniversityCollaborator
- The Central Hospital of Lishui CityCollaborator
- People's Hospital of QuzhouCollaborator
- Zhoushan Maternity and Infant HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.